our launch on readiness Thank I you, Today, activities. Julian, and everyone. and good morning, will review manufacturing our progress
As therapy, to need stem patients we our breakthrough an allogeneic continue cell for in of omidubicel advance transplant.
BLA what relationship This with will clear our includes which required be our a be facilities owned Cell commercial Israel on contractual Gamida Type with a and commercial XXXX, feedback facility ready Lonza. During B we meeting our facility for FDA manufacturing December, we in the for in submission. for have received to
these Given X of Phase facilities need commercial important trial, facilities preparing commercial to for facilities the We've these both that of used demonstrate progress for we clinical were manufacturing made the omidubicel with manufacturing comparability registration from these neither supply. commercial readiness.
state-of-the-art since me construction milestones with facility. has Let The was has completed team start our internal completed. facility our our Israeli achieved of and timeline each construction been
with engineering qualified simulation team, second our we We and the for our anticipate have qualification. process our and PPQs quarter of aseptic first runs a of performance hired, the and has quarter required methods or analytical and validations third this team completion production and during of in are the quarter initial successfully runs process completed The XXXX 'XX. in finalizing year, underway trained compatibility planned qualification
For program the access Lonza and requirements. facility, BLA our commercial expanded progressing currently on we the are clinical batches are manufacturing for
currently patients were who are believe which the hematological market about a for there are marketing viewed eligibility Physician in strategy. sites, the be an based extensive the for significant for We opportunity patients sources. three is important based with and not the in on increasing other encouraging are decrease compared outcomes with year. access clinical Upon fourth second, research hospitalizations More submit with clinical payer was and There based there product disease by on will the are an graft sources in and patients on-track transplant omidubicel our there of specifically payers XX,XXX to patients Based the transplant. engraftment, almost donor malignancies, to for the were for on current XXXX. omidubicel faster The in to they summarized neutrophil first, for opportunity host omidubicel, understand matched; published potential we grass then have who approval, omidubicel option decrease requirements be time not consider market unfortunately, we and over specifically, has increasing advantages. each been need profile BLA, to as but We can plan stem feedback the not less on strong clinical FDA omidubicel transplanted, encouraged for conducted that, encouraging infections, improving and has literature our us positively therapy develop and transplanted. in were CMC clinical quarter X,XXX launch XX,XXX addition alone versus as in actually and profile. cell are for payers, needs eligible, potential eligible data of enabled patients a categories; allogeneic U.S.
probability. partnership donors age, were We the that that statistically the utilized greater less also each years their factor to CIBMTR, is XX patient to from In with than consideration. have we real-world a survival or demonstrate transplant hear equal of a if of data in had donors physicians
at probably diagnosed above of So cord is concern. related not potentially related for members omidubicel an the be their diagnosis, a donor if XX, age is given umbilical blood, could material this AML be XX is example, of median age, the family haploidentical or donors, which age case of is the donors starting from would years who matched patient that in
for transplant. not genetic other will the donor patients access could may therapy to in transplants be otherwise find cell omidubicel to stringent provide to due sources, less allogeneic approved for who important of option marrow Additionally, compared need the from patients Omidubicel suitable criteria stem matching omidubicel an donor. a bone opportunity as expand an to
following transplant a XX% important Our up States. in since approval the FDA about positive strategy. the transplant center patients launch an centers with know that centers transplants of the caregivers. aspect our United XX strategy and goal that is of Education the experience to is centers omidubicel ensure of We the and make have transplant
We experiences. and through clinical have others know professional direct those from our XX many of experience with trial centers past
and them are payers we centers partner and on approval. ensure diligently with with the that reimbursement to upon able been endpoints to recognition with the educate we effectively be will begun have FDA We reduced as the time the positive, omidubicel importance to the the Outreach are discussions working has confident payers including US and of already data reduced secondary such infections. hospital clinical and of
we centers an process. support patients, to to caregivers outstanding team Additionally, build and the through transplant plan
on from our a be supporting excited assistance developing Cell As Julian to ensure This community. patient focused to to transplant mentioned, a progress a will patient's is like experience. Assist with team the Gamida positive other consist patients we Assist experienced journey omidubicel. that are provide for of personalized Cell will undergoing dedicated no Gamida that and program continue
Our roles. focused ensuring will experienced who patient patients, to Gamida process. Gamida provide consist a Assist The team an and the transplant each Cell Assist the and number at caregivers, of of key hospital of support case throughout management their access will team step Cell have team will on be the
will is start which the follow the Gamida Cell of The important requirements. of roles One we'll is with of that the identity, patient compliance a Assist, unique identity chain FDA's throughout chain process. patient most identifier entire the our
Just contact patients. Gamida Assist to as that going Cell point single be hospitals is and importantly, the of for
to As is journey transplant we and the will patients a needs. assistance omidubicel verification be benefits such, Gamida and as provide able their support such to access or for hospitals Cell travel to supporting and lodging patients centers. to committed positive with
they patients. approved cell marrow therapy outcomes. what successful So, matters omidubicel physicians, and patient and from are clinical the potential the were the we feedback by of payers experience for can We the bone and the and focus FDA to most be transplants, excited encouraged clinical by data on first
our to our a omidubicel center over place on now will positive Shai experience. results. with I to assuring plan focus in a the transplant patient have turn and review strategy call We and financial launch key
